On our screens:Stocks with no debt
Is the price fair?
What KRYS's price assumes
Krystal Biotech, Inc. trades at 44.0× earnings against 31.5× for the median Biotechnology name, more expensive than its own group.
44.0
Trailing P/E · Biotechnology median 31.5 · 1.40× the median: the market pays up for this one
- Price / sales
- 10.1
Price / sales · as of 2025-FY
- Free cash flow yield
- 2.4%
Free cash flow yield · Biotechnology median 2.4%
- Growth the price implies
- +15%
Growth the price implies · What free cash flow would have to do every year for a decade to justify today's price, discounted at 9.0%.
Details›
- Price / book2025-FY
- 6.05
- Healthcare median P/E362 names
- 29.9
- Biotechnology median P/E158 names
- 31.5
- Free cash flow, trailing twelve months
- $258M
- Market capitalisation
- $10.6B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.